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•  Four women dropped out of the study due to domestic matters (n=2) and drug-related side effects (Parkinson type 
symptoms and gallbladder pain) (n=2). 
 
• The two women who completed the study had large drops in their maximum daily pain (VAS). 
 
• One woman (FA) changed her pain report from baseline of 85 to 0 on the VAS after the 14-week trial. 
 
• The other subject (SM) VAS pain report dropped to 0 (from 100) two-weeks after completing the study. 
 
• Significant drops in percent awake hours in pain were also observed in both subjects; FA dropped from 30% to 5% 
while SM dropped from 100% to 0%. 
 
• Subject FA had unremitting pain for 5 years. Ten weeks into the trial at 200mg of thalidomide she had a large drop in 
her VAS pain report and remained pain free for two months after trial termination. 
 
• SM reported unremitting pain for 8 years. While she remained highly symptomatic during the trial (VAS= 100), she 
had 2 months of pain remission 3 weeks after completing the study. 
 
• The two women who dropped from the study due to side effects at eight weeks indicated improvement in their pelvic 
pain.  
 
• Two of the participants opted to continue thalidomide therapy off protocol. 
Endometriosis affects 2.5-3.3% of reproductive age women and 
is a common diagnosis among women with chronic pelvic pain. 
Treatment for endometriosis ranges from conservative medical 
therapies to radical surgery. Endometriosis is an indication for 
25-35% of laparoscopies and 10-15% of hysterectomies each 
year . Although the majority of women with endometriosis 
respond to conservative medical therapy, those with persistent 
pain often undergo hysterectomy. Based on clinical and 
experimental data that indicate that thalidomide may be a highly 
effective immune modulator, we sought to investigate the 
efficacy and tolerability of this novel therapy for endometriosis 
associated pain patients who desired fertility-sparing treatment 
after exhausting all other conservative modalities. 
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OBJECTIVE 
Division of Advanced Laparoscopy and Pelvic Pain, Department of Obstetrics and Gynecology,  
University of North Carolina at Chapel Hill School of Medicine 
To investigate the efficacy and tolerability of thalidomide as a 
treatment for endometriosis associated pain patients 
Thalidomide may be useful in treating persistent endometriosis associated pelvic pain. Additional studies are 
warranted. 
BACKGROUND 
Six women with biopsy proven endometriosis and chronic pelvic 
pain were enrolled from August 2006 to May 2007. Participants 
had tried conventional therapeutics such as oral contraceptive 
therapy, GnRh-agonist, and/or treatment with Danazol, but these 
therapies had failed to treat their symptoms. Thus, they had been 
offered hysterectomy as a last resort. Enrolled subjects reported 
daily maximal pain of ≥ 60 on the Visual Analog Scale (VAS).  
 
Two of the six eligible women completed the 14 week open label 
trial with thalidomide (dose range of 50mg to 250mg). 
Participants were assessed weekly for pain and drug tolerability. 
Table 1: Summary of Results 
 Subject 1 (FA) Subject 2 (SM) 
Time of Previous Unremitting Pain  5 years 8 years 
Baseline Pain Report (VAS)  85 100 
Time when Pain Report (VAS) equaled 0 14 weeks (end of study) 2 weeks post-study 
Change in % Wake Hours in Pain 30%  5% 100%  0% 
Continued Thalidomide post-study Yes Yes 
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